JPRN-UMIN000036255已完成未知
The Efficacy and Safety of Alectinib in Clinical Practice ; Comparision to Crizotinib, in A Multicenter Retrospective Study. - The efficacy of alectinib in a multicenter retrospective study
Respiratory Centor, Matsusaka Municipal Hospital0 个研究点目标入组 61 人开始时间: 2019年3月19日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 61
研究概览
简要总结
Sixty-one patients were enrolled. Forty-six patients were treated with ALK inhibitors (31 with crizotinib, 28 with alectinib, and 13 with both ALK inhibitors). The response rate was 66.7% for the crizotinib-treated group and 80.8% for the alectinib-treated group. Among all patients, TTF and PFS were significantly prolonged in the alectinib-treated group compared with in the crizotinib-treated group. OS was significantly longer in the alectinib-treated group than in the crizotinib-treated group.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
已完成
2 期
A Study of the Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung CancerCarcinoma, Non-Small-Cell LungNCT03155009Hoffmann-La Roche44
已完成
不适用
PhaseII safety and efficacy study of alectinib in poor performance status patients with ALK positive, advanced NSCLCon-Small Cell Lung CancerJPRN-UMIN000015094ung Oncology Group in Kyushu, Japan (LOGIK)17
已完成
2 期
A-LiquidJPRN-jRCT2080225060Department of Thoracic Oncology, National Cancer Center Hospital East25
招募中
2 期
Clinical Trial of Alectinib in Patients with ALK positive rare cancerRare cancers harboring ALK gene alterationsJPRN-jRCT2091220364ational Cancer Center Hospital26
已完成
不适用
Retrospective study of alectinib on long-term prognosis in poor performance status patients with ALK positive, advanced/recurrent NSCLCon-Small Cell Lung CancerJPRN-UMIN000035853ung Oncology Group in Kyushu, Japan (LOGIK)18